NasdaqGS:QURE 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	19	-297	71	0
31 Dec 23	16	-308	75	0
30 Sep 23	112	-228	75	0
30 Jun 23	112	-187	71	0
31 Mar 23	110	-157	62	0
31 Dec 22	106	-127	55	0
30 Sep 22	61	-125	51	0
30 Jun 22	62	-114	49	0
31 Mar 22	525	324	55	0
31 Dec 21	524	330	56	0
30 Sep 21	500	321	54	0
30 Jun 21	500	303	52	0
31 Mar 21	38	-139	46	0
31 Dec 20	38	-125	43	0
30 Sep 20	6	-166	40	0
30 Jun 20	5	-136	38	0
31 Mar 20	6	-124	35	0
31 Dec 19	7	-124	34	0
30 Sep 19	6	-105	32	0
30 Jun 19	8	-103	29	0
31 Mar 19	9	-92	27	0
31 Dec 18	11	-83	25	0
30 Sep 18	12	-90	26	0
30 Jun 18	11	-78	25	0
31 Mar 18	13	-78	25	0
31 Dec 17	13	-79	25	0
30 Sep 17	20	-67	24	0
30 Jun 17	25	-72	23	0
31 Mar 17	24	-71	26	0
31 Dec 16	25	-73	25	0
30 Sep 16	20	-76	28	0
30 Jun 16	16	-90	29	0
31 Mar 16	14	-90	26	0
31 Dec 15	11	-82	23	0
30 Sep 15	8	-76	18	0
30 Jun 15	6	-58	16	0
31 Mar 15	5	-45	14	0
31 Dec 14	6	-50	17	0
30 Sep 14	5	-41	15	0
30 Jun 14	6	-42	17	0
31 Mar 14	6	-41	17	0
31 Dec 13	4	-37	16	0
30 Sep 13	3	-33	10	-7

양질의 수익: QURE 은(는) 현재 수익성이 없습니다.

이익 마진 증가: QURE 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: QURE 은(는) 수익성이 없으며 지난 5년 동안 연간 12% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 QURE 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: QURE 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: QURE 현재 수익성이 없기 때문에 마이너스 자본 수익률( -202.29% )을 갖습니다.

uniQure 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Recent updates

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 15%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

uniQure N.V., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

CEO & Executive Director recently sold US$177k worth of stock

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO & Executive Director notifies of intention to sell stock

Consensus revenue estimates decrease by 33%, EPS upgraded

New minor risk - Share price stability

uniQure: The Valuation Got More Attractive

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease

A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

Consensus revenue estimates fall by 35%

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Consensus revenue estimates decrease by 23%

Consensus revenue estimates fall by 55%

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Operating Officer notifies of intention to sell stock

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

uniQure N.V. Announces Executive Changes

New minor risk - Share price stability

Consensus revenue estimates increase by 12%

Consensus revenue estimates fall by 36%

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

CEO & Executive Director notifies of intention to sell stock

Consensus EPS estimates fall by 16%

CEO & Executive Director recently sold US$493k worth of stock

CEO & Executive Director notifies of intention to sell stock

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Independent Non-Executive Director exercised options and sold US$103k worth of stock

Independent Non-Executive Director exercised options and sold US$143k worth of stock

CEO & Executive Director recently sold US$149k worth of stock

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Independent Non-Executive Director notifies of intention to sell stock

uniQure N.V. Highlights Therapeutic Potential of Amt-260 in Refractory Temporal Lobe Epilepsy (Rtle) At Virtual Research & Development Event

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Consensus revenue estimates fall by 51%

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Insider exercised options and sold US$123k worth of stock

Investor sentiment improved over the past week

uniQure N.V. Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Investor sentiment improved over the past week

Chief Operating Officer recently sold US$100k worth of stock

Chief Operating Officer notifies of intention to sell stock

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

Consensus revenue estimates fall by 44%